Global Lisinopril Market 2023-2030

    In Stock

    Coming Soon




    Angiotensin-converting enzyme (ACE) inhibitors are a group of medicines that includes the drug lisinopril. Heart failure and hypertension are its two main indications for use. Lisinopril lowers blood pressure and improves blood flow to the heart by relaxing the blood vessels.


     With or without food, lisinopril is typically taken once day. It’s crucial to take lisinopril precisely as directed by your physician. Without first talking to your doctor, you shouldn’t stop taking lisinopril.


    Lisinopril’s side effects can include nausea, vomiting, dry cough, fatigue, headache, and dizziness. Consult your doctor if you suffer any negative effects while taking lisinopril.


    Other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), potassium supplements, and diuretics, may interact with lisinopril.


    Before starting lisinopril, it’s crucial to let your doctor know about all the drugs you’re taking, including over-the-counter medicines and dietary supplements.




    infographic: Lisinopril Market, Lisinopril Market Size, Lisinopril Market Trends, Lisinopril Market Forecast, Lisinopril Market Risks, Lisinopril Market Report, Lisinopril Market Share


    Global lisinopril market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.



    Because ACE inhibitors like lisinopril are said to raise levels of ACE-2, the protein that the SARs-CoV-2 virus attaches to, they may enhance the likelihood of COVID-19 complications.


    The risk of a heart attack or stroke, however, surpasses the hypothetical possibility of worse COVID-19 results by a significant margin[1]. There is no proof, according to, that ACE inhibitors raise the risk of COVID-19 complications.


    Another possible explanation for why those with high blood pressure are more prone to get pulmonary side  and effects from COVID-19 is an overactive renin-angiotensin system. Nevertheless, during the COVID-19 pandemic, quitting ACE inhibitor use has a higher risk than continuing it.


    In conclusion, the hypothesis that ACE medications enhance the incidence of COVID-19 problems is unfounded.


    The risk of a heart attack or stroke and hemorrhage from stopping these medications outweighs the potential risk of worse COVID-19 outcomes by a significant margin.


    Another factor that may contribute to the increased risk of pulmonary COVID-19 problems in those with high blood pressure is the possibility of an overactive renin-angiotensin system.



    • AstraZeneca
    • Merck Sharp & Dohme Corp
    • Silvergate Pharmaceuticals, Inc
    • Acme Formulation Pvt. Ltd
    • Orchid Chemicals & Pharmaceuticals Ltd
    • Novartis India Ltd
    • Cadila Pharmaceuticals Ltd
    • Hexal AG
    • Mylan Pharmaceuticals



    1. How many lisinopril are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global lisinopril and key vendor selection criteria
    3. Where is the lisinopril manufactured? What is the average margin per unit?
    4. Market share of Global lisinopril market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global lisinopril in-house
    6. key predictions for next 5 years in Global lisinopril market
    7. Average B-2-B lisinopril market price in all segments
    8. Latest trends in lisinopril market, by every market segment
    9. The market size (both volume and value) of the lisinopril market in 2023-2030 and every year in between?
    10. Production breakup of lisinopril market, by suppliers and their OEM relationship


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop